Ultragenyx Pharmaceutical IncNASDAQ:RARE
- LAST PRICE45.0200
- TODAY'S CHANGE (%)0.3100 (0.6934%)
- Bid / Lots43.9800/ 1
- Ask / Lots46.1900/ 1
- Open / Previous Close44.8900 / 44.7100
- Day Range
- 52 Week Range
- Volume746,998
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RARE |
|---|---|---|
| 09:32 ET | 2811 | 44.94 |
| 09:34 ET | 900 | 44.93 |
| 09:36 ET | 400 | 44.955 |
| 09:38 ET | 2993 | 44.495 |
| 09:39 ET | 700 | 44.405 |
| 09:41 ET | 1400 | 44.2725 |
| 09:43 ET | 600 | 44.26 |
| 09:45 ET | 1500 | 44.5 |
| 09:48 ET | 4122 | 44.54 |
| 09:50 ET | 2095 | 44.665 |
| 09:52 ET | 1900 | 44.82 |
| 09:54 ET | 1500 | 44.81 |
| 09:56 ET | 630 | 44.74 |
| 09:57 ET | 1200 | 44.5 |
| 10:01 ET | 4400 | 44.485 |
| 10:03 ET | 1465 | 44.51 |
| 10:06 ET | 1366 | 44.415 |
| 10:08 ET | 800 | 44.42 |
| 10:10 ET | 700 | 44.35 |
| 10:12 ET | 415 | 44.335 |
| 10:14 ET | 914 | 44.485 |
| 10:15 ET | 400 | 44.44 |
| 10:17 ET | 571 | 44.47 |
| 10:19 ET | 400 | 44.55 |
| 10:21 ET | 1051 | 44.53 |
| 10:24 ET | 1426 | 44.485 |
| 10:26 ET | 1933 | 44.49 |
| 10:30 ET | 500 | 44.5 |
| 10:32 ET | 5846 | 44.515 |
| 10:33 ET | 4082 | 44.64 |
| 10:35 ET | 1332 | 44.63 |
| 10:37 ET | 2654 | 44.665 |
| 10:39 ET | 5204 | 44.5 |
| 10:42 ET | 1707 | 44.495 |
| 10:44 ET | 2725 | 44.621 |
| 10:46 ET | 400 | 44.59 |
| 10:48 ET | 1144 | 44.63 |
| 10:50 ET | 400 | 44.63 |
| 10:51 ET | 1800 | 44.735 |
| 10:53 ET | 300 | 44.755 |
| 10:55 ET | 2305 | 44.72 |
| 10:57 ET | 2286 | 44.8 |
| 11:00 ET | 1268 | 44.98 |
| 11:02 ET | 445 | 45.035 |
| 11:04 ET | 937 | 45.045 |
| 11:06 ET | 600 | 44.97 |
| 11:08 ET | 100 | 44.915 |
| 11:09 ET | 200 | 44.941 |
| 11:11 ET | 200 | 44.84 |
| 11:13 ET | 100 | 44.925 |
| 11:18 ET | 400 | 44.88 |
| 11:20 ET | 544 | 44.83 |
| 11:22 ET | 410 | 44.88 |
| 11:26 ET | 3033 | 44.845 |
| 11:27 ET | 2740 | 44.72 |
| 11:29 ET | 1210 | 44.75 |
| 11:31 ET | 3200 | 44.775 |
| 11:33 ET | 2014 | 44.845 |
| 11:36 ET | 3324 | 45.07 |
| 11:38 ET | 600 | 45.14 |
| 11:40 ET | 2000 | 45.24 |
| 11:42 ET | 400 | 45.32 |
| 11:44 ET | 1580 | 45.42 |
| 11:45 ET | 943 | 45.37 |
| 11:47 ET | 500 | 45.37 |
| 11:49 ET | 100 | 45.37 |
| 11:51 ET | 1400 | 45.5 |
| 11:54 ET | 836 | 45.48 |
| 11:56 ET | 865 | 45.47 |
| 11:58 ET | 3284 | 45.4 |
| 12:00 ET | 1560 | 45.565 |
| 12:02 ET | 1041 | 45.61 |
| 12:03 ET | 1752 | 45.455 |
| 12:05 ET | 620 | 45.365 |
| 12:07 ET | 200 | 45.39 |
| 12:09 ET | 100 | 45.44 |
| 12:12 ET | 11100 | 45.62 |
| 12:14 ET | 800 | 45.66 |
| 12:16 ET | 400 | 45.65 |
| 12:18 ET | 1545 | 45.69 |
| 12:20 ET | 2143 | 45.65 |
| 12:21 ET | 100 | 45.645 |
| 12:25 ET | 200 | 45.645 |
| 12:27 ET | 1700 | 45.63 |
| 12:32 ET | 200 | 45.6 |
| 12:34 ET | 804 | 45.615 |
| 12:36 ET | 2000 | 45.665 |
| 12:38 ET | 200 | 45.63 |
| 12:39 ET | 2655 | 45.63 |
| 12:41 ET | 900 | 45.57 |
| 12:43 ET | 4234 | 45.54 |
| 12:45 ET | 411 | 45.6 |
| 12:48 ET | 500 | 45.66 |
| 12:50 ET | 738 | 45.69 |
| 12:52 ET | 700 | 45.68 |
| 12:54 ET | 2092 | 45.675 |
| 12:56 ET | 800 | 45.6775 |
| 12:57 ET | 2583 | 45.62 |
| 12:59 ET | 200 | 45.53 |
| 01:03 ET | 100 | 45.55 |
| 01:08 ET | 200 | 45.51 |
| 01:10 ET | 100 | 45.52 |
| 01:12 ET | 2455 | 45.435 |
| 01:14 ET | 200 | 45.485 |
| 01:15 ET | 100 | 45.465 |
| 01:17 ET | 100 | 45.44 |
| 01:19 ET | 144 | 45.465 |
| 01:21 ET | 400 | 45.39 |
| 01:24 ET | 428 | 45.335 |
| 01:26 ET | 8167 | 45.27 |
| 01:28 ET | 1500 | 45.42 |
| 01:30 ET | 800 | 45.5 |
| 01:32 ET | 1745 | 45.58 |
| 01:33 ET | 4543 | 45.57 |
| 01:35 ET | 400 | 45.535 |
| 01:37 ET | 100 | 45.59 |
| 01:39 ET | 2000 | 45.6 |
| 01:42 ET | 800 | 45.65 |
| 01:44 ET | 1000 | 45.65 |
| 01:46 ET | 1700 | 45.68 |
| 01:48 ET | 4455 | 45.54 |
| 01:50 ET | 200 | 45.46 |
| 01:51 ET | 1100 | 45.55 |
| 01:53 ET | 6823 | 45.595 |
| 01:55 ET | 29413 | 45.62 |
| 01:57 ET | 100 | 45.65 |
| 02:00 ET | 801 | 45.745 |
| 02:02 ET | 2700 | 45.76 |
| 02:04 ET | 1598 | 45.99 |
| 02:06 ET | 3282 | 45.855 |
| 02:08 ET | 100 | 45.91 |
| 02:09 ET | 1447 | 45.765 |
| 02:11 ET | 1300 | 45.74 |
| 02:13 ET | 1019 | 45.67 |
| 02:15 ET | 543 | 45.62 |
| 02:18 ET | 1441 | 45.645 |
| 02:20 ET | 133 | 45.64 |
| 02:22 ET | 200 | 45.675 |
| 02:24 ET | 400 | 45.68 |
| 02:26 ET | 1200 | 45.72 |
| 02:27 ET | 2997 | 45.6 |
| 02:29 ET | 605 | 45.58 |
| 02:31 ET | 100 | 45.58 |
| 02:33 ET | 2180 | 45.845 |
| 02:38 ET | 3100 | 45.77 |
| 02:40 ET | 200 | 45.77 |
| 02:42 ET | 200 | 45.74 |
| 02:44 ET | 2094 | 45.83 |
| 02:45 ET | 506 | 46.02 |
| 02:47 ET | 400 | 46.12 |
| 02:49 ET | 787 | 46.17 |
| 02:51 ET | 706 | 46.25 |
| 02:56 ET | 1743 | 46.425 |
| 02:58 ET | 100 | 46.48 |
| 03:00 ET | 750 | 46.47 |
| 03:02 ET | 800 | 46.505 |
| 03:03 ET | 1329 | 46.57 |
| 03:05 ET | 1761 | 46.455 |
| 03:07 ET | 3087 | 46.46 |
| 03:09 ET | 206 | 46.45 |
| 03:12 ET | 5346 | 46.36 |
| 03:14 ET | 1600 | 46.45 |
| 03:16 ET | 503 | 46.4353 |
| 03:18 ET | 1700 | 46.375 |
| 03:20 ET | 916 | 46.31 |
| 03:21 ET | 2373 | 46.37 |
| 03:23 ET | 3129 | 46.305 |
| 03:25 ET | 1482 | 46.08 |
| 03:27 ET | 2750 | 46.075 |
| 03:30 ET | 2000 | 45.83 |
| 03:32 ET | 4187 | 45.66 |
| 03:34 ET | 1031 | 45.76 |
| 03:36 ET | 2050 | 45.74 |
| 03:38 ET | 4152 | 45.6 |
| 03:39 ET | 4542 | 45.61 |
| 03:41 ET | 1230 | 45.66 |
| 03:43 ET | 4392 | 45.6525 |
| 03:45 ET | 3941 | 45.67 |
| 03:48 ET | 3460 | 45.62 |
| 03:50 ET | 4890 | 45.695 |
| 03:52 ET | 5642 | 45.655 |
| 03:54 ET | 5716 | 45.28 |
| 03:56 ET | 7409 | 45.2 |
| 03:57 ET | 10474 | 45.16 |
| 03:59 ET | 144496 | 45.02 |
Jul 25, 2024
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update, from 4:05PM ET on Thursday Jul 25, 2024 by Dow Jones
4:05PM ET on Thursday Jul 25, 2024 by Dow Jones
Jul 24, 2024
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium, from 8:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
8:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
Jul 23, 2024
DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 7:52AM ET on Tuesday Jul 23, 2024 by Dow Jones
7:52AM ET on Tuesday Jul 23, 2024 by Dow Jones
Jul 22, 2024
DJ Ultragenyx Pharma Price Target Maintained With a $115.00/Share by Cantor Fitzgerald, from 11:53AM ET on Monday Jul 22, 2024 by Dow Jones
11:53AM ET on Monday Jul 22, 2024 by Dow Jones
Jul 19, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Jul 19, 2024 by Dow Jones
4:05PM ET on Friday Jul 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ultragenyx Pharmaceutical Inc | 4.2B | -5.6x | --- |
Apellis Pharmaceuticals Inc | 4.8B | -11.4x | --- |
CRISPR Therapeutics AG | 4.8B | -21.2x | --- |
Guardant Health Inc | 4.4B | -9.0x | --- |
Axsome Therapeutics Inc | 4.0B | -13.7x | --- |
Amicus Therapeutics Inc | 3.0B | -20.9x | --- |
Company Information
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Contact Information
- Headquarters
- 60 Leveroni CtNOVATO, CA, United States 94949-5746
- Phone
- 415-483-8800
- Fax
- 415-483-8810
Executives
- Independent Director
- Daniel Welch
- President, Chief Executive Officer, Director
- Emil Kakkis
- Chief Financial Officer, Executive Vice President
- Howard Horn
- Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
- Dennis Huang
- Executive Vice President, Chief Legal Officer, General Counsel
- Karah Parschauer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
|---|---|
Revenue (TTM) | $442.6M |
Shares Outstanding | 93.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-8.02 |
Book Value | $3.35 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | 9.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -131.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
